Mavrilimumab

Mavrilimumab is a human monoclonal antibody[1] that inhibits human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R).[2]

Mavrilimumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetGM-CSF receptor alpha chain
Clinical data
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6706H10438N1762O2104S54
Molar mass151140.74 g·mol−1
 NY (what is this?)  (verify)

Mavrilimumab was discovered as CAM-3001 by Cambridge Antibody Technology and is being developed by MedImmune, Inc.[1] as an investigational drug for the treatment of rheumatoid arthritis

Mavrilimumab has been studied in a phase 1 dose-ranging trial[2] and a phase 2a clinical trial, both sponsored by Medimmune.[3] The phase 2a trial, which studied mavrilimumab doses of up to 100 mg, reported that 55.7% of subjects met the primary endpoint of a ≥1.2 decrease from baseline in disease activity scores at week 12 (vs. only 34.7% of placebo subjects).[3]

In 2013, two further clinical studies were reported to be underway in rheumatoid arthritis patients to investigate these effects further.[4]

In early 2017 the phase IIb study was reported to be showing promising results.[5]

It was studied in 2020 to see if it could improve the prognosis for patients with COVID-19 pneumonia and systemic hyperinflammation. One small study indicated some beneficial effects of treatment with mavrilimumab compared with those who were not.[6]

References
  1. "Statement On A Nonproprietary Name Adopted By The USAN Council: Mavrilimumab" (PDF). American Medical Association. Archived from the original (PDF) on 2012-09-28.
  2. Burmester GR, Feist E, Sleeman MA, Wang B, White B, Magrini F (September 2011). "Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study". Annals of the Rheumatic Diseases. 70 (9): 1542–9. doi:10.1136/ard.2010.146225. PMC 3147227. PMID 21613310.
  3. Burmester GR, Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, et al. (EARTH Study Group) (September 2013). "Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis". Annals of the Rheumatic Diseases. 72 (9): 1445–52. doi:10.1136/annrheumdis-2012-202450. PMC 3756523. PMID 23234647.
  4. Di Franco M, Gerardi MC, Lucchino B, Conti F (12 March 2014). "Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis". Core Evidence. 9: 41–8. doi:10.2147/CE.S39770. PMC 3958547. PMID 24648832.
  5. Walsh N (February 21, 2017). "Agent that Targets GM-CSF Shows Promise in RA". MedPage Today. Novel monoclonal antibody was rapidly effective in mild-to-moderate disease
  6. De Luca G, Cavalli G, Campochiaro C, Della-Torre E, Angelillo P, Tomelleri A, et al. (16 June 2020). "GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study". The Lancet Rheumatology. doi:10.1016/S2665-9913(20)30170-3.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.